← Back to Clinical Trials
Recruiting NCT07622069

NCT07622069 Diagnosis, Determining Factors, and Characteristics of Pathologies Associated With Autoinflammatory Diseases.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07622069
Status Recruiting
Phase
Sponsor Hospices Civils de Lyon
Condition Rare Autoinflammatory Disease
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2025-09-09
Primary Completion 2028-08-15

Eligibility & Interventions

Sex All sexes
Min Age 4 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2025-09-09 with a primary completion date of 2028-08-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Autoinflammatory diseases are part of a heterogeneous group of diseases that manifest themselves through an inflammatory reaction in their initial phase (innate immunity) that is activated inappropriately: either because the reaction is too strong or because it is unjustified (for example, in the absence of infection). In many cases, and in their initial description, autoinflammatory diseases have a genetic origin (and are therefore hereditary or familial) and preferentially affect children or young adults. However, a significant number of other diseases have expanded this nosological field due to the preponderance of autoinflammation in explaining the symptoms. Sometimes, autoinflammatory disease can also remain "unclassified." In general, autoinflammatory diseases manifest as recurrent attacks combining fever, skin rashes, and joint pain. Certain signs are more specific to certain diseases, such as hives, abdominal pain, mouth ulcers, or swollen lymph nodes in the neck. It is mainly the recurrence of attacks and their unprovoked nature that attract the attention of the patient and the doctor. These attacks are systematically associated with an increase in inflammatory markers in the blood. Currently, most autoinflammatory diseases are diagnosed based on a combination of clinical and biological evidence, following a thorough investigation by specialists in these diseases. Biological markers that can confirm the disease are rare. However, for some of them, confirmation can be obtained through genetic analysis. In certain cases, extensive genetic analysis may be offered. Autoinflammatory diseases are managed by specialists (internists, rheumatologists, etc.) in close collaboration with primary care physicians and other healthcare professionals (nurses, physical therapists, social workers, etc.). Treatment is sometimes based on exceptional drugs that can only be prescribed and dispensed in hospitals. This multicenter, national study, which targets children and adults with rare autoinflammatory diseases, aims to identify: * the "key" parameters for a faster diagnosis, * the determining factors and their associated characteristics, and * the treatments used and their effectiveness.

Eligibility Criteria

Inclusion Criteria: \- Adult patient \> 18 years old Minor patient (aged 4 years and 6 months to 18 years) Patient diagnosed with a rare autoinflammatory disease Patient treated at the Hospices Civils de Lyon in the department participating in the research Patient affiliated with social security Exclusion Criteria: * none

Frequently Asked Questions

Who can join the NCT07622069 clinical trial?

This trial is open to participants of all sexes, aged 4 Years or older, studying Rare Autoinflammatory Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07622069 currently recruiting?

Yes, NCT07622069 is actively recruiting participants. Visit ClinicalTrials.gov or contact Hospices Civils de Lyon to inquire about joining.

Where is the NCT07622069 trial being conducted?

This trial is being conducted at Lyon, France.

Who is sponsoring the NCT07622069 clinical trial?

NCT07622069 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology